Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study-Reference-Cited by-同舟云学术

Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study

Published:2017-10 Issue:10 Volume:28 Page:2581-2587
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Chapman P.B.,Robert C.,Larkin J.,Haanen J.B.,Ribas A.,Hogg D.,Hamid O.,Ascierto P.A.,Testori A.,Lorigan P.C.,Dummer R.,Sosman J.A.,Flaherty K.T.,Chang I.,Coleman S.,Caro I.,Hauschild A.,McArthur G.A.

Funder

F. Hoffmann-La Roche Ltd

NCI

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/28/10/2581/25113639/mdx339.pdf

Reference18 articles.

1. Improved survival with vemurafenib in melanoma with BRAF V600E mutation;Chapman;N Engl J Med,2011

2. Combined vemurafenib and cobimetinib inBRAF-mutated melanoma;Larkin;N Engl J Med,2014

3. Dabrafenib inBRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial;Hauschild;Lancet,2012

4. Trametinib for patients with advanced melanoma;Masuda;Lancet Oncol,2012

5. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma;Long;N Engl J Med,2014

Cited by 195 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Therapy Innovations for Melanoma;Hematology/Oncology Clinics of North America;2024-10

2. Successful treatment of MAP2K1 mutant stage IV-M1d melanoma with trametinib plus low-dose dabrafenib: a case report;Frontiers in Medicine;2024-09-09

3. Advancements in Melanoma Therapies: From Surgery to Immunotherapy;Current Treatment Options in Oncology;2024-07-27

4. Review on radiomic analysis in 18F-fluorodeoxyglucose positron emission tomography for prediction of melanoma outcomes;Cancer Imaging;2024-07-05

5. The evolving landscape of tissue‐agnostic therapies in precision oncology;CA: A Cancer Journal for Clinicians;2024-05-30